Zydus Cadila has received final USFDA approval to market antihistamine Cyproheptadine Hydrochloride tablets in the US market. The tablets are used to relieve allergy symptoms such as hives, watery eyes, sneezing and itching eyes or nose. The company will market Cyproheptadine Hydrochloride tablets in the strength of 4 mg. The drug will be produced at the group’s formulation manufacturing facility at the pharma SEZ in Ahmedabad. The group now has around 115 approvals from USFDA and has so far filed 300 abbreviated new drug applications (ANDAs).
Company Profile : Cadila Healthcare Ltd
Leave a Reply